Premium
Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high‐dose therapy
Author(s) -
Brioli Annamaria,
Boyd Kevin D.,
Kaiser Martin F.,
Pawlyn Charlotte,
Wu Ping,
Gregory Walter M.,
Owen Roger,
Ross Fiona M.,
Jackson Graham H.,
Cavo Michele,
Davies Faith E.,
Morgan Gareth J.
Publication year - 2013
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.12218
Subject(s) - medicine , multiple myeloma , thalidomide , oncology , autologous stem cell transplantation , transplantation , clinical trial , adverse effect